These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21996981)

  • 21. Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation.
    Chung BH; Hong YA; Sun IO; Piao SG; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
    Ren Fail; 2012; 34(8):974-9. PubMed ID: 22817654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose rituximab for recurrent glomerulonephritis post-renal transplant.
    Spinner ML; Bowman LJ; Horwedel TA; Delos Santos RB; Klein CL; Brennan DC
    Am J Nephrol; 2015; 41(1):37-47. PubMed ID: 25634230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
    Twombley K; Pokala H; Ardura MI; Harker-Murray P; Johnson-Welch SF; Weinberg A; Seikaly M
    Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.
    Kanzelmeyer NK; Maecker-Kolhoff B; Zierhut H; Lerch C; Verboom M; Haffner D; Pape L
    Transpl Int; 2018 Apr; 31(4):367-376. PubMed ID: 28906028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indications for use and safety of rituximab in childhood renal diseases.
    Tullus K; Marks SD
    Pediatr Nephrol; 2013 Jul; 28(7):1001-9. PubMed ID: 22992983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience.
    Shirakawa H; Ishida H; Shimizu T; Omoto K; Iida S; Toki D; Tanabe K
    Clin Transplant; 2011; 25(6):878-84. PubMed ID: 21175849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
    Novikov PI; Krivosheev OG; Semenkova EN
    Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABO-incompatible kidney transplantation.
    Schousboe K; Titlestad K; Baudier F; Hansen LU; Bistrup C
    Dan Med Bull; 2010 Oct; 57(10):A4197. PubMed ID: 21040684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of recurrent focal segmental glomerulosclerosis with a low dose rituximab in a kidney transplant recipient.
    Cho JH; Lee JH; Park GY; Lim JH; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Ren Fail; 2014 May; 36(4):623-6. PubMed ID: 24502587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
    Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
    Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
    Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
    Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].
    Imai E
    Nihon Jinzo Gakkai Shi; 2012; 54(5):593-7. PubMed ID: 22991838
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
    Sugiyama K; Hyodo Y; Aikawa A
    Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.